248 related articles for article (PubMed ID: 10688842)
1. The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor.
Dahlgren C; Christophe T; Boulay F; Madianos PN; Rabiet MJ; Karlsson A
Blood; 2000 Mar; 95(5):1810-8. PubMed ID: 10688842
[TBL] [Abstract][Full Text] [Related]
2. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2.
Christophe T; Karlsson A; Dugave C; Rabiet MJ; Boulay F; Dahlgren C
J Biol Chem; 2001 Jun; 276(24):21585-93. PubMed ID: 11285256
[TBL] [Abstract][Full Text] [Related]
3. The peptide Trp-Lys-Tyr-Met-Val-D-Met activates neutrophils through the formyl peptide receptor only when signaling through the formylpeptide receptor like 1 is blocked. A receptor switch with implications for signal transduction studies with inhibitors and receptor antagonists.
Karlsson J; Fu H; Boulay F; Bylund J; Dahlgren C
Biochem Pharmacol; 2006 May; 71(10):1488-96. PubMed ID: 16549058
[TBL] [Abstract][Full Text] [Related]
4. Histamine inhibits neutrophil NADPH oxidase activity triggered by the lipoxin A4 receptor-specific peptide agonist Trp-Lys-Tyr-Met-Val-Met.
Betten A; Dahlgren C; Hermodsson S; Hellstrand K
Scand J Immunol; 2003 Sep; 58(3):321-6. PubMed ID: 12950678
[TBL] [Abstract][Full Text] [Related]
5. Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4.
Christophe T; Karlsson A; Rabiet MJ; Boulay F; Dahlgren C
Scand J Immunol; 2002 Nov; 56(5):470-6. PubMed ID: 12410796
[TBL] [Abstract][Full Text] [Related]
6. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.
Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
Biochem Pharmacol; 2007 Oct; 74(7):1050-6. PubMed ID: 17692291
[TBL] [Abstract][Full Text] [Related]
7. The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8.
Fu H; Bylund J; Karlsson A; Pellmé S; Dahlgren C
Immunology; 2004 Jun; 112(2):201-10. PubMed ID: 15147563
[TBL] [Abstract][Full Text] [Related]
8. Differential activation of formyl peptide receptor signaling by peptide ligands.
Bae YS; Song JY; Kim Y; He R; Ye RD; Kwak JY; Suh PG; Ryu SH
Mol Pharmacol; 2003 Oct; 64(4):841-7. PubMed ID: 14500740
[TBL] [Abstract][Full Text] [Related]
9. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation.
Le Y; Gong W; Li B; Dunlop NM; Shen W; Su SB; Ye RD; Wang JM
J Immunol; 1999 Dec; 163(12):6777-84. PubMed ID: 10586077
[TBL] [Abstract][Full Text] [Related]
10. Differential signaling of formyl peptide receptor-like 1 by Trp-Lys-Tyr-Met-Val-Met-CONH2 or lipoxin A4 in human neutrophils.
Bae YS; Park JC; He R; Ye RD; Kwak JY; Suh PG; Ho Ryu S
Mol Pharmacol; 2003 Sep; 64(3):721-30. PubMed ID: 12920210
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Trp-Nle-Tyr-Met as a novel agonist for human formyl peptide receptor-like 1.
Wan HX; Zhou C; Zhang Y; Sun M; Wang X; Yu H; Yang X; Ye RD; Shen JK; Wang MW
Biochem Pharmacol; 2007 Jul; 74(2):317-26. PubMed ID: 17517377
[TBL] [Abstract][Full Text] [Related]
12. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor.
He R; Tan L; Browning DD; Wang JM; Ye RD
J Immunol; 2000 Oct; 165(8):4598-605. PubMed ID: 11035102
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporin H, Boc-MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor.
Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
Inflammation; 2007 Dec; 30(6):224-9. PubMed ID: 17687636
[TBL] [Abstract][Full Text] [Related]
14. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling.
Bae YS; Lee HY; Jo EJ; Kim JI; Kang HK; Ye RD; Kwak JY; Ryu SH
J Immunol; 2004 Jul; 173(1):607-14. PubMed ID: 15210823
[TBL] [Abstract][Full Text] [Related]
15. The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding.
Yan P; Nanamori M; Sun M; Zhou C; Cheng N; Li N; Zheng W; Xiao L; Xie X; Ye RD; Wang MW
J Immunol; 2006 Nov; 177(10):7050-8. PubMed ID: 17082621
[TBL] [Abstract][Full Text] [Related]
16. Low-affinity receptor-mediated induction of superoxide by N-formyl-methionyl-leucyl-phenylalanine and WKYMVm in IMR90 human fibroblasts.
Ammendola R; Russo L; De Felice C; Esposito F; Russo T; Cimino F
Free Radic Biol Med; 2004 Jan; 36(2):189-200. PubMed ID: 14744631
[TBL] [Abstract][Full Text] [Related]
17. F2L, a peptide derived from heme-binding protein, inhibits formyl peptide receptor-mediated signaling.
Lee HY; Lee SY; Shin EH; Kim SD; Kim JM; Lee MS; Ryu SH; Bae YS
Biochem Biophys Res Commun; 2007 Aug; 359(4):985-90. PubMed ID: 17577578
[TBL] [Abstract][Full Text] [Related]
18. Differential activation of formyl peptide receptor-like 1 by peptide ligands.
Bae YS; Yi HJ; Lee HY; Jo EJ; Kim JI; Lee TG; Ye RD; Kwak JY; Ryu SH
J Immunol; 2003 Dec; 171(12):6807-13. PubMed ID: 14662886
[TBL] [Abstract][Full Text] [Related]
19. The endogenous opioid spinorphin blocks fMet-Leu-Phe-induced neutrophil chemotaxis by acting as a specific antagonist at the N-formylpeptide receptor subtype FPR.
Liang TS; Gao JL; Fatemi O; Lavigne M; Leto TL; Murphy PM
J Immunol; 2001 Dec; 167(11):6609-14. PubMed ID: 11714831
[TBL] [Abstract][Full Text] [Related]
20. Tumour necrosis factor (TNF)-alpha primes murine neutrophils when triggered via formyl peptide receptor-related sequence 2, the murine orthologue of human formyl peptide receptor-like 1, through a process involving the type I TNF receptor and subcellular granule mobilization.
Onnheim K; Bylund J; Boulay F; Dahlgren C; Forsman H
Immunology; 2008 Dec; 125(4):591-600. PubMed ID: 18710405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
